Surrozen announced publication of data in eLife highlighting the potential to enhance Wnt-signal activation in new targeted SWEETS, Surrozen Wnt signal Enhancer Engineered for Tissue Specificity, bispecific antibodies which utilize a unique protein degradation platform that provides alternatives for future clinical applications. This publication presented research that was focused on extending previous work by Surrozen scientists on fusing an RSPO2 mutant protein to an antibody that binds ASGR1 which led to hepatocyte-specific enhanced signaling, proliferation, and restored liver function in mouse models. In this publication, the authors described the development of two new ASGR bispecific antibodies which revealed distinct epitopes on both ASGR1 and ASGR2 that resulted in a robust and cell-specific Wnt-signal activation.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SRZN:
- Surrozen Publishes Study in ‘eLife’ Demonstrating the Promise of The Proprietary SWEETS Platform, a Unique Targeted Protein Degradation Technology, to Further Enhance Wnt Signaling
- Surrozen Presents Preliminary Results from Phase 1a Study of SZN-043 in Healthy Volunteers and Patients with a History of Liver Cirrhosis at the 2024 European Association for the Study of the Liver (EASL) in Milan
- Surrozen presents preliminary results from Phase 1a study of SZN-043
- Surrozen initiates dosing of first patient in Phase 1b trial of SZN-043
- Surrozen Initiates Dosing of First Patient in Phase 1b Clinical Trial of SZN-043 for Severe Alcohol-Associated Hepatitis